A detailed history of Sandy Spring Bank transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sandy Spring Bank holds 2 shares of NTLA stock, worth $24. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 2 -0.0%
Holding current value
$24
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$23.82 - $32.8 $2,382 - $3,279
-100 Reduced 98.04%
2 $0
Q4 2023

Jan 26, 2024

BUY
$23.16 - $32.34 $2,316 - $3,234
100 Added 5000.0%
102 $3,000
Q1 2023

May 05, 2023

SELL
$33.3 - $44.82 $3,463 - $4,661
-104 Reduced 98.11%
2 $0
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $3,520 - $6,645
106 New
106 $3,000
Q2 2019

Aug 01, 2019

SELL
$13.88 - $18.41 $13,880 - $18,410
-1,000 Closed
0 $0
Q1 2018

May 04, 2018

BUY
$19.43 - $34.95 $19,430 - $34,950
1,000 New
1,000 $21,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.